• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    C

    Corcept Therapeutics

    企业
    142论文总数
    3,183引用总数

    .

    论文量&引用量时间轴

    机构学者

    论文(142)

    年份
    起
    –
    止
    排序
    1Pharmacological Characterization of Clinical Candidate CORT118335 (miricorilant), a Selective Glucocorticoid Receptor Modulator, in Short-Term Preclinical Models for MASLD
    Tijmen J.A. Moll,Max Gentenaar,Eva MG. Viho, Anna T. Hoekstra, Salwa Afkir, Josine N. Deurloo, Paul VQ. Laman, Amber W. Schonk, Machiel W. Henst,Hazel J. Hunt,Onno C. Meijer,Jan Kroon

    CORT118335 (miricorilant) is a selective glucocorticoid receptor (GR) modulator (SGRM) that is currently being evaluated in clinical trials for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD), based on strong efficacy in mouse models. We reveal gene-specific GR modulation by CORT118335 in the mouse liver. In cell-based models, we evaluated the biological activity of CORT118335 metabolites. Metabolite CORT118335-P9a showed potent GR agonism, while metabolite CORT118335-P9b was largely inactive. CORT118335-P9a concentrations in the mouse liver were very low, and therefore neither metabolite is likely to contribute to the beneficial effects of CORT118335 in vivo. We investigated various aspects of CORT118335 activity in reducing lipid levels in the mouse liver using a model of short-term high-fat diet feeding. Daily administration of CORT118335 appeared to lower hepatic triglyceride rapidly within several days after treatment initiation, specifically in male mice, and these effects were reversed after 7 days of treatment discontinuation. No synergy was observed between the lipid-lowering effects of CORT118335 and the TRβ agonist VK2809 or the PPARγ agonist pioglitazone. At a dose of 6 mg/kg/day, CORT118335 induced evident transcriptional effects with modest lowering of hepatic triglyceride levels, while higher doses induced a more pronounced lipid lowering but less ongoing transcriptional activity for hepatic lipid metabolism genes. Altogether we substantiate the potential of selective GR modulation using CORT118335 as a lipid-lowering strategy in MASLD and highlight the complexity of SGRM-mediated hepatic lipid lowering.

    2027European Journal of Pharmacology(2027)
    引用
    AI阅读
    加入学术空间
    2TMPRSS2-ERG Confers Resistance of Prostate Cancer to Antiandrogens
    Arunachalam Sekar, Boobash Raj Selvadurai, Rishita Chatterjee, Lipika Pal,Aakanksha Verma,Nishanth Belugali Nataraj, Diana Drago Garcia,Suvendu Giri, Alessandro Genna, Feride Karatekin, Nitin Gupta, Deepthi Ramesh-Kumar,

    Approximately 50% of prostate cancer (PCa) patients harbor fusions involving the TMPRSS2 and ERG genes. Despite this, tailored therapies targeting the fused gene, tERG, remain undeveloped. Our study analyzed biopsy samples from two clinical trials assessing the efficacy of androgen receptor (AR) signaling inhibitors (ARSIs). The results revealed that tERG promotes resistance to ARSIs and is associated with elevated levels of the glucocorticoid receptor (GR). Subsequent assays showed that GR directly interacts with tERG, alleviates allosteric autoinhibition, and prevents chemotherapy-induced tERG degradation. In PCa models, either inhibiting GR or lowering cortisol levels suppressed tumor growth in tERG-positive models, but not in tERG-negative models. In addition, patient-derived fusion-positive xenografts displayed enhanced sensitivity to combined GR and AR inhibitors. Collectively, these findings highlight TMPRSS2-ERG as a new biomarker and propose that simultaneous inhibition of GR and AR may specifically benefit tERG-positive patients. However, GR stimulatory corticosteroid therapies may not be advisable for this patient subgroup.

    2026EMBO Molecular Medicine(2026)引用:65
    引用
    AI阅读
    加入学术空间
    3Efficacy and Safety of Relacorilant for the Treatment of Patients with Cushing's Syndrome (GRACE): a Multicentre, Phase 3, Double-Blind, Placebo-Controlled, Randomised-Withdrawal Study
    Rosario Pivonello,Giorgio Arnaldi, Richard J Auchus,Corin Badiu,Robert S Busch,Salvatore Cannavò,Ulrich Dischinger, Georgiana A Dobri, Diane M Donegan,Atanaska Elenkova,Pouneh K Fazeli, Richard A Feelders,

    BACKGROUND:Relacorilant is a selective glucocorticoid receptor modulator designed to reduce excess cortisol activity by competing with cortisol for glucocorticoid receptor binding, mitigating the clinical manifestations of endogenous hypercortisolism (Cushing's syndrome). The aim of this study was to assess the efficacy and safety of relacorilant in adults with endogenous hypercortisolism. METHODS:This multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal study enrolled adults with endogenous hypercortisolism and hypertension, hyperglycaemia, or both and was conducted at 77 study centres across 11 countries. Key inclusion criteria included being aged 18-80 years with at least two clinical signs or symptoms of hypercortisolism. In the open-label phase, patients received oral, once-daily relacorilant (escalation from 100 mg up to 400 mg) for 22 weeks. Patients who met response criteria were randomly assigned (1:1) by the interactive web response system to continue relacorilant 400 mg (or highest tolerated dose) or placebo for 12 weeks in the randomised-withdrawal phase. Participants and investigators were masked to treatment assignment. The primary outcome was the proportion of patients who lost hypertension response during the randomised-withdrawal phase compared between relacorilant and placebo at week 12. As per protocol, this outcome was assessed in all participants who received at least one dose of study drug in the study period (intention-to-treat population). Missing randomised-withdrawal week 12 values were considered a loss of response. Safety was assessed in all enrolled patients who received at least one dose of study drug in that period. This study is registered with ClinicalTrials.gov, NCT03697109. FINDINGS:Between Oct 16, 2018, and April 15, 2024, 404 patients were screened, 152 were enrolled, and 95 completed the open-label relacorilant phase. 62 patients met response criteria and were randomly assigned to relacorilant (30 total participants [21 met hypertension response criteria]) or placebo (32 total participants [22 met hypertension response criteria]). In the 30 participants in the relacorilant group, the mean age was 46·6 years (SD 11·0), 22 (73%) were female, and eight (27%) were male. In the 32 participants in the placebo group, the mean age was 48·8 years (SD 14·4), 26 (81%) were female, and six (19%) were male. During the randomised-withdrawal phase, significantly more patients with baseline hypertension who were randomly assigned to placebo lost hypertension control compared with those who continued relacorilant (proportion difference 34%; odds ratio 0·17 [95% CI 0·04-0·77]; p=0·022). In the randomised-withdrawal phase safety population, the most common adverse events in the 30 participants given relacorilant and the 32 participants given placebo were back pain (5 [17%] vs 6 [19%]), acne (3 [10%] vs 0), arthralgia (3 [10%] vs 3 [9%]), bursitis (3 [10%] vs 0), headache (3 [10%] vs 4 [13%]), and insomnia (0 vs 4 [13%]). There were no cases of excessive glucocorticoid receptor antagonism, adrenal insufficiency, vaginal bleeding associated with endometrial hypertrophy, drug-induced hypokalaemia, or drug-induced QT interval prolongation. INTERPRETATION:Patients treated with relacorilant were more likely to maintain hypertension control compared with patients treated with placebo. The findings support consideration of relacorilant as a therapeutic option to reduce the harmful and debilitating effects of endogenous hypercortisolism. FUNDING:Corcept Therapeutics.

    2026The lancet Diabetes & endocrinology(2026)引用:2
    引用
    AI阅读
    加入学术空间
    4Evaluation of Relacorilant As a Glucocorticoid Receptor Modulator for Maintenance Therapy Following Standard First-Line Treatment in Ovarian Cancer Organoid Models
    Sarah Joy Baron,Sonali Kaushik,Hazel Hunt, Rebecca Herberston, Kate Lankester, Melanie Sarah Flint
    2026INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER(2026)引用:1
    引用
    AI阅读
    加入学术空间
    5Real-world Comparative Effectiveness of Nab-Paclitaxel and Paclitaxel in Combination with Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer (COMPASS)
    Robert Coleman,Raina Mathur, Anju Parthan, Prakirthi Yerram, Amanda Kesner-Hays, Rachel Myers,Iulia Cristina Tudor, Darin Dobler, Adrian Jubb, Mark Shahin
    2026GYNECOLOGIC ONCOLOGY(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 142 篇论文

    合作机构(100)

    莱顿大学合作论文 16
    密歇根大学合作论文 14
    芝加哥大学合作论文 11
    斯坦福大学合作论文 10
    匹兹堡大学合作论文 9
    瓦尔德希布伦大学医院合作论文 9
    威斯康星医学院合作论文 8
    华盛顿大学合作论文 6
    都灵大学合作论文 6
    德克萨斯大学西南医学中心合作论文 6

    机构统计